Universal Beteiligungs und Servicegesellschaft mbH Lowers Stock Holdings in Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR)

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH reduced its holdings in Structure Therapeutics Inc. (NASDAQ: GPCR) by 32.6% during Q1, leaving them with 76,863 shares valued at approximately $1.33 million.
• A recent earnings report revealed that Structure Therapeutics missed expectations, reporting an EPS of ($0.27) against a consensus estimate of ($0.24).
• Analysts maintain a consensus "Buy" rating for Structure Therapeutics, with target prices ranging from $60 to $89, while the current consensus target price is $76.17.

Universal Beteiligungs und Servicegesellschaft mbH lowered its holdings in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) by 32.6% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 76,863 shares of the company's stock after selling 37,129 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.13% of Structure Therapeutics worth $1,330,000 at the end of the most recent reporting period.

Other hedge funds also recently bought and sold shares of the company. LPL Financial LLC lifted its position in shares of Structure Therapeutics by 6.0% in the fourth quarter. LPL Financial LLC now owns 11,485 shares of the company's stock valued at $311,000 after acquiring an additional 646 shares in the last quarter. Nomura Asset Management Co. Ltd. lifted its position in shares of Structure Therapeutics by 25.5% in the fourth quarter. Nomura Asset Management Co. Ltd. now owns 36,925 shares of the company's stock valued at $1,001,000 after acquiring an additional 7,496 shares in the last quarter. Franklin Resources Inc. lifted its position in shares of Structure Therapeutics by 4.5% in the fourth quarter. Franklin Resources Inc. now owns 738,090 shares of the company's stock valued at $20,017,000 after acquiring an additional 31,984 shares in the last quarter. Headlands Technologies LLC purchased a new position in shares of Structure Therapeutics in the fourth quarter valued at approximately $113,000. Finally, Geode Capital Management LLC lifted its position in shares of Structure Therapeutics by 1.1% in the fourth quarter. Geode Capital Management LLC now owns 45,705 shares of the company's stock valued at $1,240,000 after acquiring an additional 480 shares in the last quarter. Hedge funds and other institutional investors own 91.78% of the company's stock.

Structure Therapeutics Stock Performance

Shares of Structure Therapeutics stock opened at $17.80 on Friday. The business's 50 day moving average price is $20.57 and its 200 day moving average price is $22.27. The company has a market cap of $1.02 billion, a price-to-earnings ratio of -20.46 and a beta of -1.87. Structure Therapeutics Inc. Sponsored ADR has a one year low of $13.22 and a one year high of $45.37.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last posted its earnings results on Thursday, May 8th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.03). On average, analysts predict that Structure Therapeutics Inc. Sponsored ADR will post -0.82 EPS for the current fiscal year.

Analyst Ratings Changes

Several equities analysts have recently weighed in on GPCR shares. HC Wainwright decreased their target price on Structure Therapeutics from $80.00 to $75.00 and set a "buy" rating on the stock in a research report on Monday, May 12th. Cantor Fitzgerald reiterated an "overweight" rating and set a $65.00 price objective on shares of Structure Therapeutics in a research report on Monday, June 23rd. JMP Securities reiterated a "market outperform" rating and set a $89.00 price objective on shares of Structure Therapeutics in a research report on Monday, June 23rd. Finally, Citigroup assumed coverage on Structure Therapeutics in a research report on Friday, May 2nd. They set a "buy" rating and a $60.00 price objective on the stock. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $76.17.

Structure Therapeutics Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.

Want to see what other hedge funds are holding GPCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.